More Than a Billion People Smoke Tobacco
In a piece of news that should hearten the cigarette industry and send chills down the spines of world health officials, a new study claims that a billion adults smoke tobacco worldwide.
In a piece of news that should hearten the cigarette industry and send chills down the spines of world health officials, a new study claims that a billion adults smoke tobacco worldwide.
Investors are not too happy with Intercept Pharmaceuticals after it released the terms for its most recent clinical trial.
Eleven Biotherapeutics released its most recent clinical trial results, and its drug candidate did not meet either of its two co-primary endpoints.
Investors, doctors and cancer patients are anxiously awaiting some of the key presentations and abstracts from the American Society of Clinical Oncology (ASCO) annual meeting.
AcelRX announced that it entered into a contract with the U.S. Army Medical Research and Material Command within the Department of Defense. The contract is worth up to $17 million.
Cowen sees the potential for super-mergers in biotech, as well as a large group of smaller targets that may be in the sights of bigger companies now.
Orexigen Therapeutics shares plunge after termination of cardiovascular outcomes study of the obesity drug Contrave.
ThinkstockSometimes, or lots of times, investors and markets take things a little too far. For instance, a stock might overreact, to the upside or downside, based on too much optimism or pessimism. The market…
Oppenheimer sees an upside of about triple the current share price of Tokai Pharmaceuticals, based on what it has coming out in its pipeline.
Pain Therapeutics has announced top-line results for an FDA Category 3 Human Abuse Potential Study with Remoxy Extended-Release Capsules CII.
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Credit Suisse expects that biotech stocks will see the most promotions in the coming rebalance of the Russell Indexes.
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
ThinkstockAny time that you hear about new drugs and medical treatments, they tend to be around ongoing treatments rather than cures. And when it comes to AIDS and HIV, the past has been cruel…
Among speculative small-cap biotechs, analyst calls are often accompanied with upside price targets of 50%, 100% or even 200%. This is because the companies are often all-in bets on one or two treatments.